190 related articles for article (PubMed ID: 22120230)
1. Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.
Yong RL; Lonser RR
World Neurosurg; 2012; 77(5-6):636-8. PubMed ID: 22120230
[No Abstract] [Full Text] [Related]
2. Dendritic cell vaccines to combat glioblastoma.
Wheeler CJ
Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
[No Abstract] [Full Text] [Related]
3. Dendritic cell immunotherapy for glioblastoma.
Polyzoidis S; Ashkan K
Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
[TBL] [Abstract][Full Text] [Related]
4. Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma.
Nakano I; Chiocca EA
World Neurosurg; 2012; 77(5-6):633-5. PubMed ID: 22120228
[No Abstract] [Full Text] [Related]
5. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
[TBL] [Abstract][Full Text] [Related]
6. Trials and tribulations of cancer immunotherapy: the dendritic cell vaccine shows promise in a phase I glioblastoma multiforme trial.
Gürsel DB; Schlaff CD; Boockvar JA
Neurosurgery; 2012 Dec; 71(6):N19-21. PubMed ID: 23160396
[No Abstract] [Full Text] [Related]
7. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in human glioblastoma.
Szabo AT; Carpentier AF
Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
[TBL] [Abstract][Full Text] [Related]
10. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
[TBL] [Abstract][Full Text] [Related]
11. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Schaller TH; Sampson JH
Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
[TBL] [Abstract][Full Text] [Related]
12. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
Van Gool S; De Vleeschouwer S
Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
[No Abstract] [Full Text] [Related]
13. Current status of immunotherapy and gene therapy for high-grade gliomas.
Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
[TBL] [Abstract][Full Text] [Related]
14. Agenus cancer vaccine extends survival of GBM patients.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(2):252-3. PubMed ID: 24963517
[No Abstract] [Full Text] [Related]
15. Cellular-based immunotherapies for patients with glioblastoma multiforme.
Xu X; Stockhammer F; Schmitt M
Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
[TBL] [Abstract][Full Text] [Related]
16. An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments.
Coxon AT; Johanns TM; Dunn GP
Mo Med; 2020; 117(1):45-49. PubMed ID: 32158049
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
Ajay D; Sanchez-Perez L; Choi BD; De Leon G; Sampson JH
Curr Drug Discov Technol; 2012 Dec; 9(4):237-55. PubMed ID: 22339070
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-based immunotherapy for glioblastoma.
Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
[TBL] [Abstract][Full Text] [Related]
19. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Reardon DA; Mitchell DA
Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
[TBL] [Abstract][Full Text] [Related]
20. First results on the DCVax phase III trial: raising more questions than providing answers.
Wick W; van den Bent MJ
Neuro Oncol; 2018 Sep; 20(10):1283-1284. PubMed ID: 30137551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
